Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 15 | 2023 | 259 | 2.810 |
Why?
|
| Ultrasonography | 15 | 2025 | 243 | 2.450 |
Why?
|
| Point-of-Care Systems | 6 | 2025 | 62 | 2.070 |
Why?
|
| Abscess | 4 | 2020 | 28 | 1.980 |
Why?
|
| Soft Tissue Infections | 3 | 2020 | 23 | 1.800 |
Why?
|
| Fibrinolytic Agents | 2 | 2025 | 59 | 1.650 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2020 | 21 | 1.310 |
Why?
|
| Humans | 53 | 2025 | 28436 | 1.270 |
Why?
|
| Heart Arrest | 2 | 2020 | 41 | 1.260 |
Why?
|
| Anti-Bacterial Agents | 6 | 2021 | 383 | 1.260 |
Why?
|
| Shoulder Dislocation | 2 | 2022 | 111 | 1.220 |
Why?
|
| Trachea | 4 | 2025 | 49 | 1.170 |
Why?
|
| Warfarin | 3 | 2022 | 26 | 1.020 |
Why?
|
| Intubation, Intratracheal | 4 | 2025 | 99 | 0.990 |
Why?
|
| Thrombectomy | 1 | 2025 | 31 | 0.950 |
Why?
|
| Endovascular Procedures | 1 | 2025 | 34 | 0.940 |
Why?
|
| Thrombolytic Therapy | 1 | 2025 | 50 | 0.940 |
Why?
|
| Hyperkalemia | 2 | 2021 | 6 | 0.890 |
Why?
|
| Blood Coagulation Factors | 3 | 2022 | 19 | 0.890 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 47 | 0.880 |
Why?
|
| Drainage | 3 | 2020 | 50 | 0.880 |
Why?
|
| Fractures, Bone | 2 | 2022 | 75 | 0.870 |
Why?
|
| Esophagus | 3 | 2022 | 65 | 0.850 |
Why?
|
| Retrospective Studies | 18 | 2023 | 3612 | 0.840 |
Why?
|
| Ventricular Fibrillation | 2 | 2020 | 15 | 0.830 |
Why?
|
| Hemorrhage | 2 | 2020 | 81 | 0.810 |
Why?
|
| Antiemetics | 1 | 2022 | 9 | 0.790 |
Why?
|
| Hypoglycemia | 2 | 2021 | 13 | 0.780 |
Why?
|
| Sympathomimetics | 1 | 2021 | 5 | 0.770 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2020 | 12 | 0.760 |
Why?
|
| Airway Management | 1 | 2021 | 15 | 0.760 |
Why?
|
| Critical Illness | 3 | 2021 | 135 | 0.760 |
Why?
|
| Ketamine | 1 | 2021 | 25 | 0.750 |
Why?
|
| Emergency Medicine | 2 | 2020 | 97 | 0.750 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 42 | 0.730 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 81 | 0.710 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 11 | 0.700 |
Why?
|
| Phenytoin | 1 | 2020 | 6 | 0.700 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 16 | 0.700 |
Why?
|
| Bites and Stings | 1 | 2020 | 4 | 0.700 |
Why?
|
| Wound Infection | 1 | 2020 | 7 | 0.700 |
Why?
|
| Skin Diseases | 1 | 2020 | 26 | 0.700 |
Why?
|
| Status Epilepticus | 1 | 2020 | 13 | 0.700 |
Why?
|
| Documentation | 1 | 2020 | 29 | 0.700 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 5 | 0.700 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2025 | 330 | 0.680 |
Why?
|
| Anticonvulsants | 1 | 2020 | 57 | 0.680 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 23 | 0.660 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 29 | 0.660 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 88 | 0.660 |
Why?
|
| Adult | 15 | 2025 | 8107 | 0.660 |
Why?
|
| Gonorrhea | 1 | 2019 | 7 | 0.650 |
Why?
|
| Chlamydia Infections | 1 | 2019 | 7 | 0.650 |
Why?
|
| Glucagon | 1 | 2019 | 7 | 0.640 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 12 | 0.640 |
Why?
|
| Aftercare | 1 | 2019 | 26 | 0.640 |
Why?
|
| Retinal Detachment | 1 | 2019 | 7 | 0.630 |
Why?
|
| Pulmonary Edema | 3 | 2023 | 26 | 0.630 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 159 | 0.630 |
Why?
|
| Epistaxis | 1 | 2018 | 9 | 0.620 |
Why?
|
| Foreign Bodies | 1 | 2019 | 30 | 0.620 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 17 | 0.610 |
Why?
|
| Male | 18 | 2023 | 15291 | 0.610 |
Why?
|
| Spinal Puncture | 1 | 2018 | 25 | 0.610 |
Why?
|
| Tranexamic Acid | 1 | 2018 | 17 | 0.610 |
Why?
|
| Skin Diseases, Infectious | 1 | 2018 | 6 | 0.600 |
Why?
|
| Anthrax | 1 | 2017 | 1 | 0.590 |
Why?
|
| Transportation of Patients | 1 | 2017 | 4 | 0.580 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 3 | 0.580 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 76 | 0.580 |
Why?
|
| Mass Casualty Incidents | 1 | 2017 | 9 | 0.580 |
Why?
|
| Health Resources | 1 | 2017 | 23 | 0.580 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 32 | 0.570 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 29 | 0.570 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 328 | 0.560 |
Why?
|
| Female | 17 | 2023 | 15730 | 0.550 |
Why?
|
| Anticoagulants | 3 | 2022 | 90 | 0.510 |
Why?
|
| Sensitivity and Specificity | 7 | 2025 | 517 | 0.500 |
Why?
|
| Middle Aged | 13 | 2023 | 9269 | 0.480 |
Why?
|
| Azoles | 1 | 2014 | 1 | 0.460 |
Why?
|
| Tacrolimus | 1 | 2014 | 15 | 0.460 |
Why?
|
| Sirolimus | 1 | 2014 | 20 | 0.460 |
Why?
|
| Antifungal Agents | 1 | 2014 | 43 | 0.450 |
Why?
|
| Treatment Failure | 3 | 2020 | 163 | 0.450 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 140 | 0.420 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 117 | 0.410 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 135 | 0.400 |
Why?
|
| Algorithms | 1 | 2014 | 377 | 0.380 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2021 | 9 | 0.370 |
Why?
|
| Metoprolol | 3 | 2020 | 8 | 0.370 |
Why?
|
| Diltiazem | 3 | 2020 | 8 | 0.370 |
Why?
|
| Prospective Studies | 5 | 2023 | 1809 | 0.360 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3615 | 0.360 |
Why?
|
| Pharmacists | 2 | 2021 | 19 | 0.360 |
Why?
|
| Aged | 9 | 2025 | 9277 | 0.360 |
Why?
|
| Intestinal Obstruction | 2 | 2023 | 12 | 0.350 |
Why?
|
| Intensive Care Units | 3 | 2021 | 306 | 0.320 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2020 | 37 | 0.320 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 116 | 0.320 |
Why?
|
| Insulin | 2 | 2021 | 90 | 0.320 |
Why?
|
| International Normalized Ratio | 3 | 2022 | 18 | 0.260 |
Why?
|
| Heart Failure | 2 | 2018 | 180 | 0.260 |
Why?
|
| Vomiting | 2 | 2023 | 17 | 0.250 |
Why?
|
| Nausea | 2 | 2023 | 24 | 0.250 |
Why?
|
| Point-of-Care Testing | 2 | 2023 | 30 | 0.240 |
Why?
|
| Chicago | 2 | 2019 | 946 | 0.240 |
Why?
|
| Intracranial Hemorrhages | 1 | 2025 | 13 | 0.240 |
Why?
|
| Bias | 1 | 2025 | 41 | 0.240 |
Why?
|
| Diverticulitis | 1 | 2025 | 5 | 0.240 |
Why?
|
| Child | 2 | 2020 | 1420 | 0.240 |
Why?
|
| Nasal Cavity | 2 | 2021 | 32 | 0.230 |
Why?
|
| Nystagmus, Pathologic | 1 | 2023 | 2 | 0.220 |
Why?
|
| Potassium | 2 | 2021 | 66 | 0.220 |
Why?
|
| Dizziness | 1 | 2023 | 18 | 0.220 |
Why?
|
| Vancomycin | 2 | 2021 | 52 | 0.210 |
Why?
|
| Blood Glucose | 2 | 2021 | 108 | 0.210 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 183 | 0.210 |
Why?
|
| Eye | 1 | 2022 | 8 | 0.200 |
Why?
|
| Metoclopramide | 1 | 2022 | 4 | 0.200 |
Why?
|
| Thrombosis | 2 | 2020 | 58 | 0.200 |
Why?
|
| Neuroimaging | 1 | 2022 | 128 | 0.190 |
Why?
|
| Cystitis | 1 | 2021 | 12 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 319 | 0.180 |
Why?
|
| Stroke Volume | 2 | 2018 | 58 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 35 | 0.180 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 33 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 22 | 0.180 |
Why?
|
| Publications | 1 | 2020 | 17 | 0.180 |
Why?
|
| Hypercalcemia | 1 | 2020 | 11 | 0.180 |
Why?
|
| Piracetam | 1 | 2020 | 8 | 0.180 |
Why?
|
| Calcitonin | 1 | 2020 | 17 | 0.180 |
Why?
|
| Job Satisfaction | 1 | 2020 | 27 | 0.180 |
Why?
|
| Diphosphonates | 1 | 2020 | 17 | 0.170 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 28 | 0.170 |
Why?
|
| Benzodiazepines | 1 | 2020 | 48 | 0.170 |
Why?
|
| Blood Coagulation | 1 | 2020 | 20 | 0.170 |
Why?
|
| Publishing | 1 | 2020 | 39 | 0.170 |
Why?
|
| Dogs | 1 | 2020 | 184 | 0.170 |
Why?
|
| Cellulitis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Seizures | 1 | 2020 | 66 | 0.170 |
Why?
|
| Young Adult | 2 | 2017 | 2069 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 73 | 0.160 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2019 | 4 | 0.160 |
Why?
|
| Chlamydia trachomatis | 1 | 2019 | 6 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 216 | 0.160 |
Why?
|
| Midodrine | 1 | 2019 | 4 | 0.160 |
Why?
|
| Bezoars | 1 | 2019 | 3 | 0.160 |
Why?
|
| Blood Pressure | 1 | 2020 | 208 | 0.160 |
Why?
|
| Peristalsis | 1 | 2019 | 12 | 0.160 |
Why?
|
| Shock | 1 | 2019 | 11 | 0.160 |
Why?
|
| Physical Examination | 1 | 2020 | 118 | 0.160 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 158 | 0.160 |
Why?
|
| Mass Screening | 1 | 2021 | 183 | 0.160 |
Why?
|
| Manipulation, Orthopedic | 1 | 2019 | 8 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2019 | 75 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2018 | 16 | 0.160 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 372 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 239 | 0.150 |
Why?
|
| Capnography | 1 | 2018 | 10 | 0.150 |
Why?
|
| Sepsis | 1 | 2020 | 144 | 0.150 |
Why?
|
| Lung | 3 | 2023 | 170 | 0.150 |
Why?
|
| Bacillus anthracis | 1 | 2017 | 1 | 0.150 |
Why?
|
| Bioterrorism | 1 | 2017 | 4 | 0.150 |
Why?
|
| Ciprofloxacin | 1 | 2017 | 12 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 14 | 0.150 |
Why?
|
| Disaster Planning | 1 | 2017 | 10 | 0.150 |
Why?
|
| Doxycycline | 1 | 2017 | 16 | 0.140 |
Why?
|
| Bandages | 1 | 2017 | 7 | 0.140 |
Why?
|
| Length of Stay | 1 | 2019 | 329 | 0.140 |
Why?
|
| Neoplasms | 1 | 2020 | 239 | 0.140 |
Why?
|
| Time Factors | 2 | 2021 | 1491 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2017 | 34 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 268 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 307 | 0.140 |
Why?
|
| Illinois | 1 | 2017 | 246 | 0.140 |
Why?
|
| Pain Measurement | 1 | 2018 | 472 | 0.130 |
Why?
|
| Infant | 1 | 2018 | 587 | 0.130 |
Why?
|
| Child, Preschool | 1 | 2018 | 688 | 0.130 |
Why?
|
| Voriconazole | 1 | 2014 | 12 | 0.120 |
Why?
|
| Fluconazole | 1 | 2014 | 9 | 0.120 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 7 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 17 | 0.110 |
Why?
|
| Mycoses | 1 | 2014 | 23 | 0.110 |
Why?
|
| Triazoles | 1 | 2014 | 29 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2019 | 1926 | 0.110 |
Why?
|
| Animals | 1 | 2020 | 3780 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 51 | 0.100 |
Why?
|
| Adolescent | 1 | 2017 | 2307 | 0.090 |
Why?
|
| Acute Disease | 2 | 2025 | 208 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 737 | 0.090 |
Why?
|
| Professional Role | 2 | 2021 | 36 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 4857 | 0.090 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 23 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 351 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 773 | 0.070 |
Why?
|
| Vertigo | 1 | 2023 | 8 | 0.060 |
Why?
|
| Pleura | 1 | 2023 | 9 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 35 | 0.050 |
Why?
|
| Glasgow Coma Scale | 1 | 2022 | 9 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2025 | 249 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 109 | 0.050 |
Why?
|
| Linezolid | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cadaver | 1 | 2022 | 376 | 0.040 |
Why?
|
| Penicillanic Acid | 1 | 2020 | 3 | 0.040 |
Why?
|
| Piperacillin | 1 | 2020 | 3 | 0.040 |
Why?
|
| Medical Records | 1 | 2020 | 34 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 117 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 60 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 168 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 141 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 28 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 196 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 396 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 260 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 199 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 323 | 0.040 |
Why?
|